^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

FCER1G inhibitor

Associations
Trials
over1year
Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction. (PubMed, SLAS Discov)
One compound, hematoxylin, was confirmed to disrupt the SYK/FECR1G interaction in an orthogonal protein-protein interaction assay. Thus, our optimized and miniaturized uHTS assay could be applied to future scaling up of a screening campaign to identify small molecule inhibitors targeting the SYK and FCER1G interaction.
Journal
|
SYK (Spleen tyrosine kinase) • FCER1G (Fc Fragment Of IgE Receptor Ig)
over1year
Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction. (PubMed, bioRxiv)
One compound, hematoxylin, was confirmed to disrupt the SYK/FECR1G interaction in an orthogonal protein-protein interaction assay. Thus, our optimized and miniaturized uHTS assay could be applied to future scaling up of a screening campaign to identify small molecule inhibitors targeting the SYK and FCER1G interaction.
Journal
|
SYK (Spleen tyrosine kinase) • FCER1G (Fc Fragment Of IgE Receptor Ig)
over2years
Identification of FCER1G as a key gene in multiple myeloma based on weighted gene co-expression network analysis. (PubMed, Hematology)
GSEA in our study indicated that FCER1G participated in NK cell mediated cytotoxicity and the NOD-like receptor signaling pathway. Our study identified FCER1G as a key gene in MM, providing a novel biomarker and potential molecular mechanisms of MM for further studies.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD68 (CD68 Molecule) • FCER1G (Fc Fragment Of IgE Receptor Ig)
almost3years
The Genetic and Immunologic Landscape Underlying the Risk of Malignant Progression in Laryngeal Dysplasia. (PubMed, Cancers (Basel))
TILs showed a highly positive correlation with CCR6, CD83, HLA-DPB1, MX1 and SNAI1, and they were inversely correlated with CD48, CIITA, CXCR4, FCER1G, IL1B, LST1 and TLR8. (4) TILs have a great potential to identify high-risk progression dysplasia and thus to define surveillance protocols and prevention programs.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • TLR8 (Toll Like Receptor 8) • CD48 (CD48 Molecule) • FCER1G (Fc Fragment Of IgE Receptor Ig) • IL1B (Interleukin 1, beta) • SNAI1 (Snail Family Transcriptional Repressor 1) • CCR6 (C-C Motif Chemokine Receptor 6) • MX1 (MX Dynamin Like GTPase 1)
almost3years
Identification and Analysis of Crucial Genes in H. pylori-Associated Gastric Cancer Using an Integrated Bioinformatics Approach. (PubMed, J Oncol)
Patients with higher levels of C3 expression had a poorer prognosis than those with lower levels. In addition, these key genes may serve as biomarkers and therapeutic targets for H. pylori-associated GC diagnosis, targeted therapy, and immunotherapy in the future.
Journal • IO biomarker
|
FCER1G (Fc Fragment Of IgE Receptor Ig) • SOSTDC1 (Sclerostin Domain Containing 1)
3years
Prognostic and immunological role of FCER1G in pan-cancer. (PubMed, Pathol Res Pract)
FCER1G can be used to predict the efficacy of immunological checkpoint therapy among these types of tumors patients. Our study also provides an important basis for the clinical use of FCER1G to assess the patient immune status and the selection of individualized immunotherapy options.
Journal • IO biomarker • Pan tumor
|
FCER1G (Fc Fragment Of IgE Receptor Ig)
|
FCER1G expression
3years
ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome (ASH 2022)
To systematically discover the determinants of this response, we analyzed single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 RS patients enrolled in a phase I study of the anti-PD1 drug nivolumab with concurrent ibrutinib (NCT 02420912). We again identified ZNF683 among the top upregulated genes in RS-R (Log2 fold change = 2.13, p=0.037), along with other genes enriched in our ZNF683high CD8 E/EM signature (BATF, CORO1A, CD38, ITGB2, GZMM), while RS-NR were enriched in NK-like genes (KLRC1, FCGR3A, KLRG1, KLRF1 and FCER1G). In conclusion, we identify ZNF683 as marking a CD8 T cell population associated with CPB response in RS blood and bone marrow and provide evidence that this transcription factor regulates key cellular pathways involved in immune anti-tumor response, with implications for understanding CPB response in RS and other malignancies.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • LMO2 (LIM Domain Only 2) • PRDM1 (PR/SET Domain 1) • CHN1 (Chimerin 1) • FCER1G (Fc Fragment Of IgE Receptor Ig) • ITGB2 (Integrin Subunit Beta 2) • KLRG1 (Killer Cell Lectin Like Receptor G1) • PRF1 (Perforin 1) • BTN3A2 (Butyrophilin Subfamily 3 Member A2) • ITGA1 (Integrin Subunit Alpha 1) • KLRC1 (Killer Cell Lectin Like Receptor C1) • TCF7 (Transcription Factor 7)
|
CD8 expression • CD8-H • PD-1 elevation
|
Opdivo (nivolumab) • Imbruvica (ibrutinib)
3years
A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes. (PubMed, J Clin Transl Hepatol)
We established a prognostic nomogram based on the heal.immune gene signature, which includes six wound healing- and immunity-related genes. This nomogram accurately predicts the OS of HCC patients.
Journal • IO biomarker
|
CD40 (CD40 Molecule) • FCER1G (Fc Fragment Of IgE Receptor Ig) • CCNB1 (Cyclin B1) • CD86 (CD86 Molecule) • ITGA5 (Integrin Subunit Alpha 5)
3years
Identification of Specific Cervical Cancer Subtypes and Prognostic Gene Sets in Tumor and Nontumor Tissues Based on GSVA Analysis. (PubMed, J Oncol)
Based on these findings, we can develop more and more effective treatments for cervical cancer patients. Based on the gene enriched pathways, we can development specific drugs targeting the pathways.
Journal
|
LDHA (Lactate dehydrogenase A) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SPP1 (Secreted Phosphoprotein 1) • ALDOA (Aldolase Fructose-Bisphosphate A) • FCER1G (Fc Fragment Of IgE Receptor Ig) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1) • SH3PXD2B (SH3 And PX Domains 2B)
over3years
Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. (PubMed, Front Mol Biosci)
Patients with a low-risk score have higher levels of tumor-infiltrating immune cells and higher expression of immune checkpoints, which may be more sensitive to immunotherapy. It provided a theoretical basis for predicting the prognosis and personalized treatment of patients with HCC.
Journal • IO biomarker
|
FCER1G (Fc Fragment Of IgE Receptor Ig)
over3years
Microarray analysis of mRNA expression profiles in liver of ob/ob mice with real-time atmospheric PM exposure. (PubMed, Environ Sci Pollut Res Int)
Our study was aimed to explore the impact of PM on the transcriptome level in the liver of ob/ob mice by atmosphere PM whole-body dynamic exposure system, and meanwhile preliminarily investigated the effects of metformin intervention in this process...They were related to insulin resistance, glucose and lipid metabolism and other liver metabolism, and also neurodegenerative diseases. This study provided valuable clues and possible protective measures to the liver damage in ob/ob mice caused by PM exposure, and further research is needed to explore the related mechanism in detail.
Preclinical • Journal
|
CD68 (CD68 Molecule) • CTSS (Cathepsin S) • FCER1G (Fc Fragment Of IgE Receptor Ig)
|
metformin
almost4years
Prognostic modeling of patients with metastatic melanoma based on tumor immune microenvironment characteristics. (PubMed, Math Biosci Eng)
Overall, a prognostic model for metastatic melanoma based on the tumor immune microenvironment characteristics was established, which left plenty of space for further studies. It could function well in helping people to understand characteristics of the immune microenvironment in metastatic melanoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • MMP9 (Matrix metallopeptidase 9) • FCER1G (Fc Fragment Of IgE Receptor Ig)
|
LAG3 expression • CTLA4 expression